

BIOCRYST PHARMACEUTICALS INC
Form 8-K
May 05, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 2, 2014

BioCryst Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-23186
(Commission
File Number)
4505 Emperor Blvd., Suite 200

62-1413174
(IRS Employer
Identification No.)

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

Durham, North Carolina 27703

(Address of Principal Executive Offices)

(919) 859-1302

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At the Annual Meeting of Stockholders (the Annual Meeting) of BioCryst Pharmaceuticals, Inc. (the Company), stockholders of the Company approved a proposal to (1) amend the Company s Stock Incentive Plan (the Stock Incentive Plan) to increase the number of shares available for issuance under the Stock Incentive Plan by 3,750,000 shares to 13,375,708 shares as of March 10, 2014 and (2) approve the performance goals under the Stock Incentive Plan to preserve the Company s ability to grant awards that meet the requirements for performance-based compensation under Section 162(m) of the Internal Revenue Code by the affirmative vote of a majority of the shares of common stock represented at the Annual Meeting in person or by proxy and entitled to vote. A detailed description of the Amended and Restated Stock Incentive Plan is included in the Company s Definitive Proxy Statement, filed March 21, 2014. A copy of the Amended and Restated Stock Incentive Plan is attached as Exhibit 10.1 and is incorporated herein by reference.

Stockholders of the Company also approved a proposal to increase the number of shares available for issuance under the Company s Employee Stock Purchase Plan (the ESPP) by 500,000 shares to 559,176 shares as of March 10, 2014 by the affirmative vote of a majority of the shares of common stock represented at the Annual Meeting in person or by proxy and entitled to vote. A detailed description of the Amended and Restated Stock Incentive Plan is included in the Company s Definitive Proxy Statement, filed March 21, 2014. A copy of the Amended and Restated ESPP is attached as Exhibit 10.2 and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company s Annual Meeting was held on May 2, 2014 for the purpose of: (i) electing three directors to serve for a term of three years and until a successor is duly elected and qualified; (ii) ratifying the selection of Ernst & Young LLP as the Company s independent registered public accountants for 2014; (iii) holding an advisory vote regarding executive compensation; (iv) approving an amendment to the Stock Incentive Plan to (A) increase the number of shares available for issuance under the Stock Incentive Plan by 3,750,000 shares to 13,375,708 shares as of March 10, 2014 and (B) approve the performance goals under the Stock Incentive Plan to preserve the Company s ability to grant awards that meet the requirements for performance-based compensation under Section 162(m) of the Internal Revenue Code; (v) approving an amendment to the Employee Stock Purchase Plan to increase the number of shares available for issuance under the Employee Stock Purchase Plan by 500,000 shares to 559,176 shares as of March 10, 2014; (vi) approving an amendment to the Company s Certificate of Incorporation to increase the authorized common stock of the Company from 95,000,000 shares to 200,000,000 shares; and (vii) transacting such other business properly brought before the meeting.

The nominees for director were elected by the following votes:

	FOR	WITHHELD
George B. Abercrombie	38,068,670	680,073
Stanley C. Erck	38,075,895	672,848
Jon P. Stonehouse	38,051,357	697,386

In addition, there were 16,309,367 broker non-votes for each director.

The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2014 was approved by the following votes:

FOR	54,054,004
AGAINST	453,548
ABSTAIN	550,558

The proposed advisory resolution regarding executive compensation was approved by the following votes:

FOR	37,015,251
AGAINST	1,100,597
ABSTAIN	632,895
BROKER NON-VOTES	16,309,367

The proposed amendment to the Company's Stock Incentive Plan to increase the number of shares available for issuance and to approve the performance goals under the Stock Incentive Plan was approved by the following votes:

FOR	27,450,799
AGAINST	10,721,727
ABSTAIN	576,217
BROKER NON-VOTES	16,309,367

The proposed increase in the number of shares available for issuance under the Company's Employee Stock Purchase Plan was approved by the following votes:

FOR	37,462,428
AGAINST	719,632

ABSTAIN	566,683
---------	---------

BROKER NON-VOTES	16,309,367
------------------	------------

The proposed amendment to the Company's Certificate of Incorporation to increase the authorized common stock of the Company from 95,000,000 shares to 200,000,000 shares was approved by the following votes:

FOR	38,429,480
AGAINST	10,151,695
ABSTAIN	6,476,935

There was no other business voted upon at the Annual Meeting.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description
10.1	BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan
10.2	BioCryst Pharmaceuticals, Inc. Amended and Restated Employee Stock Purchase Plan

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 5, 2014

BioCryst Pharmaceuticals, Inc.

By: /s/ Alane Barnes
Alane Barnes
Vice President, General Counsel, and Corporate
Secretary

EXHIBIT INDEX

Exhibit No.	Description
10.1	BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan
10.2	BioCryst Pharmaceuticals, Inc. Amended and Restated Employee Stock Purchase Plan